Data from Qilu Pharma’s Approved ALK Inhibitor for NSCLC Published in Journal

Jinan Qilu Pharma announced that results from a Phase III trial of its next-gen oral ALK receptor tyrosine kinase inhibitor (TKI) were published in an international journal. The China Phase III INSPIRE trial compared iruplinalkib to the previous standard of care, Pfizer’s crizotinib, another ALK inhibitor, as a first-line treatment for locally advanced or metastatic ALK-positive NSCLC. Iruplinalkib, which targets both the wild-type and mutant ALK fusion genes, significantly improved progression-free survival. Earlier this year, China’s NMPA approved iruplinalkib as a first-line therapy for NSCLC patients with ALK mutations. Qi Xinke (iruplinalkib tablet) is Qilu’s first innovative drug to launch. More details....

Share this with colleagues: